# Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

> **NCT05049473** · PHASE2 · UNKNOWN · sponsor: **PETHEMA Foundation** · enrollment: 100 (estimated)

## Conditions studied

- Mature B-Cell Leukemia Burkitt Type
- Burkitt Lymphoma (BL)
- Unclassifiable Lymphoma Between DCBL and BL

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Methotrexate
- **DRUG:** Dexamethasone
- **DRUG:** Iphosphamid
- **DRUG:** Vincristine
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vindesine
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Hydrocortisone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05049473
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2024-01
- **Final completion:** 2024-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049473, "Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05049473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*